This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • A Study Evaluating the Efficacy and Safety of Lent...
Clinical trial

A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease

Read time: 2 mins
Last updated:1st Jul 2013
Identifier: NCT02151526

This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to subjects with either beta-thalassemia major or severe sickle cell disease (SCD).

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Beta-Hemoglobinopathies (Sickle Cell Disease and Beta-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral Beta-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
Study Start Date: July 2013
Estimated Primary Completion Date: February 2019
Estimated Study Completion Date: February 2019

- Experimental:
LentiGlobin BB305 Drug Product

Category Value
Date last updated at source 2018-08-06
Study type(s) Interventional
Expected enrolment 7
Study start date 2013-07-01
Estimated primary completion date 2019-02-01

View full details